Stat3 Signaling Pathway Aberrancies in Pediatric AML
N/A
21 Years
Both
Leukemia
Trial Information
Stat3 Signaling Pathway Aberrancies in Pediatric AML
OBJECTIVES:
- Determine the frequency of ligand-independent phosphorylation of Stat3 in a small
cohort of samples from pediatric patients with acute myeloid leukemia including, but
not limited to, samples known to express mutated c-kit.
- Measure the level of Stat3 phosphorylation in these samples after stimulation of three
key cytokine receptors expressed on hematopoietic cells IL-6R, G-CSFR, and c-kit.
OUTLINE: Cryopreserved samples are analyzed for levels of various components of the Stat3
pathway via western blotting.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia
- One of the following karyotypes:
- t(8;21) and WT c-kit
- t(8;21) and mutant c-kit
- Normal karyotype
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Correlations between levels of pY-Stat3 and levels of upstream cytokine receptors
Safety Issue:
No
Principal Investigator
Michele S. Redell, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Texas Children's Cancer Center
Authority:
United States: Federal Government
Study ID:
CDR0000671489
NCT ID:
NCT01138332
Start Date:
September 2009
Completion Date:
Related Keywords:
- Leukemia
- childhood acute myeloid leukemia/other myeloid malignancies
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|
